Cambridge Cognition (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the explanatory note to Resolution 7 in the Notice of the Annual General Meeting (“AGM”) to be held on 28 June 2023 contained an error.
The explanatory note to Resolution 7 should have read as follows:
The shareholders are asked to approve the resolution which gives the directors the power to allot equity securities for cash, without first having to offer such securities to existing shareholders in proportion to their existing shareholdings. The authority would be limited to allotments or sales in connection with (a) a rights issue, open offer or other pre-emptive offer up to an aggregate maximum nominal amount of £114,890.78 (representing approximately 33 per cent of the entire issued share capital of the Company as at 2 June 2023, being the latest practicable date prior to publication of this document) or (b) a general disapplication up to an aggregate maximum nominal amount of £34,815.39 (representing approximately 10 per cent of the entire issued share capital of the Company as at 2 June 2023, being the latest practicable date prior to publication of this document). The authority granted by this resolution will expire upon the expiry of Resolution 6, being at the conclusion of the next Annual General Meeting of the Company.
The wording “This is similar to the authority put in place at the last Annual General Meeting of the Company which the new authority replaces.” has been removed.
All other aspects of the Notice of AGM, dated 5 June 2023, including the resolutions to be voted on by shareholders, remain unaffected.
Cambridge Cognition Holdings Plc, a neuroscience technology company, develops and markets near-patient cognitive testing techniques in the United States, United Kingdom, the European Union, and internationally.
